These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

144 related items for PubMed ID: 38785386

  • 1. A real-world prospective observational study of eptinezumab in Asian patients with migraine.
    Zhao YJ, Ong JJY, Sonu SK, Dang J, Ng CC, Herr KJ, Bose R, Jion YI.
    Headache; 2024; 64(7):810-824. PubMed ID: 38785386
    [Abstract] [Full Text] [Related]

  • 2. Efficacy, tolerability, and safety of eptinezumab in patients with a dual diagnosis of chronic migraine and medication-overuse headache: Subgroup analysis of PROMISE-2.
    Diener HC, Marmura MJ, Tepper SJ, Cowan R, Starling AJ, Diamond ML, Hirman J, Mehta L, Brevig T, Sperling B, Cady R.
    Headache; 2021 Jan; 61(1):125-136. PubMed ID: 33314079
    [Abstract] [Full Text] [Related]

  • 3. Preventive migraine treatment with eptinezumab reduced acute headache medication and headache frequency to below diagnostic thresholds in patients with chronic migraine and medication-overuse headache.
    Marmura MJ, Diener HC, Cowan RP, Tepper SJ, Diamond ML, Starling AJ, Hirman J, Mehta L, Brevig T, Cady R.
    Headache; 2021 Oct; 61(9):1421-1431. PubMed ID: 34551130
    [Abstract] [Full Text] [Related]

  • 4. Eptinezumab for prevention of chronic migraine: A randomized phase 2b clinical trial.
    Dodick DW, Lipton RB, Silberstein S, Goadsby PJ, Biondi D, Hirman J, Cady R, Smith J.
    Cephalalgia; 2019 Aug; 39(9):1075-1085. PubMed ID: 31234642
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Effectiveness and tolerability of eptinezumab in treating patients with migraine resistant to conventional preventive medications and CGRP (receptor) antibodies: a multicentre retrospective real-world analysis from Germany.
    Scheffler A, Wenzel P, Bendig M, Gendolla A, Basten J, Kleinschnitz C, Nsaka M, Lindner D, Naegel S, Burow P, Fleischmann R, Holle D.
    J Headache Pain; 2024 May 16; 25(1):79. PubMed ID: 38755541
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Real-World Patient Experience With Erenumab for the Preventive Treatment of Migraine.
    Robblee J, Devick KL, Mendez N, Potter J, Slonaker J, Starling AJ.
    Headache; 2020 Oct 16; 60(9):2014-2025. PubMed ID: 32920850
    [Abstract] [Full Text] [Related]

  • 14. Eptinezumab treatment initiated during a migraine attack is associated with meaningful improvement in patient-reported outcome measures: secondary results from the randomized controlled RELIEF study.
    McAllister P, Winner PK, Ailani J, Buse DC, Lipton RB, Chakhava G, Josiassen MK, Lindsten A, Mehta L, Ettrup A, Cady R.
    J Headache Pain; 2022 Feb 07; 23(1):22. PubMed ID: 35130832
    [Abstract] [Full Text] [Related]

  • 15. Does MIDAS reduction at 3 months predict the outcome of erenumab treatment? A real-world, open-label trial.
    De Icco R, Vaghi G, Allena M, Ghiotto N, Guaschino E, Martinelli D, Ahmad L, Corrado M, Bighiani F, Tanganelli F, Bottiroli S, Cammarota F, Sances G, Tassorelli C.
    J Headache Pain; 2022 Sep 17; 23(1):123. PubMed ID: 36115947
    [Abstract] [Full Text] [Related]

  • 16. Long-term reductions in disease impact in patients with chronic migraine following preventive treatment with eptinezumab.
    Blumenfeld A, Ettrup A, Hirman J, Ebert B, Cady R.
    BMC Neurol; 2022 Jul 08; 22(1):251. PubMed ID: 35804294
    [Abstract] [Full Text] [Related]

  • 17. Rapid resolution of migraine symptoms after initiating the preventive treatment eptinezumab during a migraine attack: results from the randomized RELIEF trial.
    Ailani J, McAllister P, Winner PK, Chakhava G, Krog Josiassen M, Lindsten A, Sperling B, Ettrup A, Cady R.
    BMC Neurol; 2022 Jun 03; 22(1):205. PubMed ID: 35659622
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Indirect Comparison of Topiramate and Monoclonal Antibodies Against CGRP or Its Receptor for the Prophylaxis of Episodic Migraine: A Systematic Review with Meta-Analysis.
    Overeem LH, Raffaelli B, Mecklenburg J, Kelderman T, Neeb L, Reuter U.
    CNS Drugs; 2021 Aug 03; 35(8):805-820. PubMed ID: 34272688
    [Abstract] [Full Text] [Related]

  • 20. Early clinical experience with eptinezumab: results of a retrospective observational study of patient response in the United States.
    Starling AJ, Kymes S, Asher D, Soni-Brahmbhatt S, Karnik-Henry M.
    BMC Neurol; 2023 Apr 20; 23(1):158. PubMed ID: 37081405
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.